{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:13:58Z","timestamp":1760908438741},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,2,27]],"date-time":"2008-02-27T00:00:00Z","timestamp":1204070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:p>Plasma cell myelomas (PMs) have a poor prognosis. Cancer\u2010testis (CT) antigens are immunogenic proteins, representing potential targets for tumor vaccination strategies. The expression of the CT antigens GAGE, MAGE\u2010A4, MAGE\u2010C1\/CT\u20107, and NY\u2010ESO\u20101 was investigated on paraffin\u2010embedded bone marrow biopsies from 219 PM and 8 monoclonal gammopathy of undetermined significance (MGUS) patients. The frequency and prognostic impact of these CT antigens were compared with known morphological prognostic markers (i.e. Mib1 labeling index) and the presence of the translocations t(4;14)(p16.3; q32) and t(11;14)(q13;q32). We show that MAGE\u2010C1\/CT\u20107 is the most prevalent CT antigen, expressed in 57% of PMs in a high percentage of tumor cells. While MAGE\u2010C1\/CT\u20107 was absent in non\u2010malignant plasma cells, plasma cells of patients with MGUS did express MAGE\u2010C1\/CT\u20107, but no other CT antigens. MAGE\u2010C1\/CT\u20107 was more frequently expressed in PMs with an elevated proliferation rate (Mib1\u00a0&gt;10%) compared to PMs with a low proliferation rate (Mib1\u00a0\u226410%, 71%<jats:italic>versus<\/jats:italic> 29%, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) and correlated with overall survival, depending on its subcellular distribution. PMs with pure cytoplasmic MAGE\u2010C1\/CT\u20107 expression showed a better prognosis (48\u00a0months <jats:italic>versus<\/jats:italic> 33\u00a0months, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05) than PMs with combined nuclear\u2010cytoplasmic or nuclear expression only. Thus, expression of MAGE\u2010C1\/CT\u20107 in patients with monoclonal gammopathies represents a predictor of outcome and overt malignant transformation. (<jats:italic>Cancer Sci<\/jats:italic> 2008; 99: 720\u2013725)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2008.00738.x","type":"journal-article","created":{"date-parts":[[2008,2,28]],"date-time":"2008-02-28T07:39:27Z","timestamp":1204184367000},"page":"720-725","source":"Crossref","is-referenced-by-count":34,"title":["MAGE\u2010C1\/CT\u20107 expression in plasma cell myeloma: Sub\u2010cellular localization impacts on clinical outcome"],"prefix":"10.1111","volume":"99","author":[{"given":"M.","family":"Tinguely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Jenni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Knights","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Korol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Rousson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Curioni Fontecedro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. B.","family":"Cogliatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G.","family":"Bittermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dommann\u2010Scherrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Renner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. M.","family":"Probst\u2010Hensch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Moch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Knuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zippelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,2,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703006"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.11.038"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3862"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1669"},{"key":"e_1_2_6_8_2","first-page":"9","article-title":"Expression of cancer\/testis (CT) antigens MAGE\u2010A1, MAGE\u2010A3, MAGE\u2010A4, CT\u20107, and NY\u2010ESO\u20101 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease","volume":"3","author":"Dhodapkar MV","year":"2003","journal-title":"Cancer Immun"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200003)30:3<803::AID-IMMU803>3.0.CO;2-P"},{"key":"e_1_2_6_10_2","first-page":"1156","article-title":"Genes encoding tumor\u2010specific antigens are expressed in human myeloma cells","volume":"94","author":"Van Baren N","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3707"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0563"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-014480"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4931"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","unstructured":"TinguelyM JenniB ReinekeTet\u00a0al.Chromosomal translocations t(4; 14) t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities \u2013 a molecular epidemiologic study on tissue microarrays.Am J Surg Pathol2007;31:690\u20136.","DOI":"10.1097\/01.pas.0000213399.87816.56"},{"key":"e_1_2_6_16_2","first-page":"77","article-title":"Utility of interphase FISH panels for routine clinical cytogenetic evaluation of chronic lymphocytic leukemia and multiple myeloma","volume":"30","author":"Cady FM","year":"2004","journal-title":"J Assoc Genet Technol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403230"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000213282.20166.13"},{"key":"e_1_2_6_19_2","volume-title":"Statistical Methods for Survival Data Analysis","author":"Lee ET","year":"1980"},{"key":"e_1_2_6_20_2","volume-title":"Pathology and Genetics of Tumours of Haematopathopoietic and Lymphoid Tissue","author":"Jaffe E","year":"2001"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22376"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.12.6919"},{"key":"e_1_2_6_23_2","first-page":"12","article-title":"Physical interaction of two cancer\u2010testis antigens, MAGE\u2010C1 (CT7) and NY\u2010ESO\u20101 (CT6)","volume":"6","author":"Cho HJ","year":"2006","journal-title":"Cancer Immun"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0809"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1655"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2006.06.020"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/bies.20289"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2008.00738.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2008.00738.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T23:30:33Z","timestamp":1697239833000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2008.00738.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,27]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1349-7006.2008.00738.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00738.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,27]]}}}